# A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer

> **NCT06840535** · PHASE1 · COMPLETED · sponsor: **Philogen S.p.A.** · enrollment: 20 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Cancer Metastatic Disease
- PSA Level Greater Than 0.2

## Interventions

- **DRUG:** [68Ga]Ga-OncoACP3

## Key facts

- **NCT ID:** NCT06840535
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-08
- **Primary completion:** 2025-10-03
- **Final completion:** 2025-10-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06840535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06840535, "A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06840535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*